These therapeutic mAbs bind to the extracellular domain of EGFR and inhibit downstream signaling of the RAS/MAPK and PI3K/AKT pathways, which promote (cancer) cell proliferation, survival and growth. This evidence concerns the gene EGFR and cancer.